Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
Manash Shankar Chatterjee, David C. Turner, Enriqueta Felip et al. · Annals of Oncology · 2016
Cited by 172 works. doi:10.1093/annonc/mdw174
Authors
- Manash Shankar Chatterjee
- David C. Turner
- Enriqueta Felip
- H. Léna
- Federico Cappuzzo
- Leora Horn
- Edward B. Garon
- Rina Hui
- Hendrik‐Tobias Arkenau
- Matthew A. Gubens
- Matthew David Hellmann
- Dezuo Dong
- Claire H. Li
- Kapil Mayawala
- Tomoko Freshwater
- Malidi Ahamadi
- Julie A. Stone
- Gregory M. Lubiniecki
- J. Zhang
- E. Im
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM
- Population Pharmacokinetics of Therapeutic Monoclonal Antibodies